No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
603207 Shanghai Xiao Fang Pharmaceutical
- 26.94
- +0.25+0.94%
Market Closed Dec 20 15:00 CST
4.31BMarket Cap21.90P/E (TTM)
27.08High26.52Low26.85KlotVolume26.52Open26.69Pre Close72.15MTurnover6.85%Turnover Ratio21.16P/E (Static)160.00MShares39.5052wk High3.62P/B1.06BFloat Cap20.5052wk Low29.36Limit Up39.20MShs Float39.50Historical High24.02Limit Down2.10%Amplitude20.50Historical Low--Dividend TTM26.87Avg Price12.32KlotAsk--Div YieldTTM100Lot Size13.57KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Xiaofang Pharmaceutical: Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Xiaofang Pharmaceutical (603207.SH): The net income in the first three quarters was 0.162 billion yuan, a 4.07% decrease compared to the same period last year.
GeLongHui October 28th | Xiao Fang Pharmaceuticals (603207.SH) announced the third quarter report of 2024, with a revenue of 0.367 billion yuan for the first three quarters, a year-on-year increase of 0.05%; net income attributable to shareholders of the listed company was 0.162 billion yuan, a year-on-year decrease of 4.07%; and basic earnings per share was 1.28 yuan.
Xiaofang Pharmaceuticals (603207.SH): The company does not have snake medicine.
On September 9, Gelonghui reported that Xiaofang Pharmaceutical (603207.SH) stated on the interactive platform that the company does not have snake medicine.
Chinese Shares Hold Steady Ahead of Manufacturing Data; Xiaofang Pharmaceutical Soars 167% on Debut
Express News | Leading topical medicine manufacturer Xiao Fang Pharmaceuticals today listed on the Shanghai Stock Exchange. The gross margin of its main business exceeds 60%.